Peer-reviewed veterinary case report
Pretreatment D-dimer levels predict survival in dogs with lymphoma
By Boyé, Pierre et al.·Published in Veterinary and comparative oncology·2021·OCR (Oncovet-Clinical-Research), France·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Prognostic value of pretreatment plasma D-dimer level in dogs with intermediate to high-grade non-Hodgkin lymphoma.
- Species:
- dog
Plain-English summary
A group of 48 dogs diagnosed with intermediate to high-grade non-Hodgkin lymphoma (NHL) had their pretreatment D-dimer levels measured to see if it could predict their survival. The study found that 44% of the dogs had high D-dimer levels, which were linked to shorter survival times. Dogs with D-dimer levels above 0.5 µg/mL had a median progression-free survival of just 54 days compared to 104 days for those with lower levels. This suggests that higher D-dimer levels could indicate a worse prognosis for dogs with this type of cancer, but more research is needed to confirm these results.
People also search for: dog lymphoma prognosis · high D-dimer levels in dogs · non-Hodgkin lymphoma treatment for dogs
Abstract
Pretreatment D-dimer levels have been reported to predict survival in several types of malignancies in human patients. The objective of this study was to evaluate the prognostic value of pretreatment D-dimer level in dogs with intermediate to high-grade non-Hodgkin lymphoma (NHL). In a prospective, randomized, double-blind study of F14512 vs etoposide phosphate, we assessed the prognostic value of pretreatment plasma D-dimer level in 48 client-owned dogs diagnosed with intermediate to high-grade NHL. The correlation between pretreatment plasma D-dimer level and various clinical features, progression-free survival (PFS) and overall survival (OS) was analysed. The median value of pretreatment plasma D-dimer level was 0.4 μg/mL (range: 0.1-14.3 μg/mL). High pretreatment plasma D-dimer level (>0.5 μg/mL) was detected in 44% (21/48) of dogs. High D-dimer levels were not correlated with naive vs relapsed lymphoma, clinical stage, substage, immunophenotype or treatment group. D-dimer levels >0.5 μg/mL were significantly associated with inferior median PFS (54 vs 104 days, P = .011) and OS (93 vs 169 days, P = .003). In the multivariate analysis, high D-dimer levels remained an independent predictor for worse PFS (HR: 3.21, 95% CI: 1.57-6.56, P = .001) and OS (HR: 3.87, 95% CI: 1.88-7.98; P < .001). This study suggests that pretreatment plasma D-dimer level can serve as a predictor of prognosis in dogs with intermediate to high-grade NHL. Further studies are warranted to confirm these findings.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/32643242/